Petros Pharmaceuticals Inc 2026年季度报告

(Mark One) ☒Quarterly Report Pursuant to Section13 or 15(d)of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2026 Or ☐Transition Report Pursuant to Section13 or 15(d)of the Securities Exchange Act of 1934for the transition period fromtoCommission File Number: 001-39752 Petros Pharmaceuticals,Inc. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to suchfiling requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405of Regulation S-T (section 232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule12b-2 of the Exchange Act. Accelerated filer☐Smallerreportingcompany☒Emerginggrowthcompany☒ Largeacceleratedfiler☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As of May 12, 2026, there were 42,372,260 shares of the registrant’s common stock, par value $0.0001 per share, outstanding. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q may contain or incorporate by reference forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements are based uponmanagement’s assumptions, expectations, projections, intentions and beliefs about future events. Except for historicalinformation, the use of predictive, future-tense or forward-looking words such as “intend,” “plan,” “predict,” “may,”“will,” “project,” “target,” “strategy,” “estimate,” “anticipate,” “believe,” “expect,” “continue,” “potential,” “forecast,”“should” and similar expressions, whether in the negative or affirmative, that reflect our current views with respect tofuture events and operational, economic and financial performance are intended to identify such forward-lookingstatements. Such forward-looking statements are only predictions, and actual results and the timing of certain eventsand circumstances may differ materially from those described by the forward-looking statements as a result of risksand uncertainties, including, without limitation, Petros’ ability to execute on its business strategy, including its plans todevelop and commercialize a proprietary Rx-to-OTC switch technology; Petros’ ability to comply with obligations as apublic reporting company; the ability of Petros to timely and effectively implement controls and procedures requiredby Section 404 of the Sarbanes-Oxley Act of 2002; risks resulting from Petros’ status as an emerging growth company,including that reduced disclosure requirements may make shares of Petros’ common stock, par value $0.0001 per share(“Common Stock”), less attractive to investors; risks related to Petros’ ability to continue as a going concern; risksrelated to Petros’ history of incurring significant losses; risks related to Petros’ ability to obtain regulatory approvalsfor, or market acceptance of, its Rx-to-OTC switch technology. Additional factors that could cause actual results todiffer materially from the results anticipated in these forward-looking statements are described in this Quarterly Reporton Form 10-Q, in “Risk Factor Summary” and in Part I, Item 1A., “Risk Factors,” in Petros’Annual Report on Form10-K for the year ended December 31, 2025, and in our other reports filed with the Securities and ExchangeCommission (the “SEC”). We advise you to carefully review the reports and documents we file from time to time withthe SEC, particularly our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q and our current reportson Form 8-K. Petros cautions readers that the forward-looking statements included in, or incorporated by referenceinto, this Quarterly Report on Form 10-Q represent our beliefs, expectations, estimates and as